Abstract 163P
Background
Next generation sequencing (NGS) technologies allow for a better understanding of tumors’ biology and the implementation of targeted therapy (TT). We conducted a prospective investigational project at the Catalan Institut of Oncology-Badalona to assess their clinical utility in ABC.
Methods
After obtaining the informed consent of patients (pts) with ABC, Oncomine Comprehensive AssayV3 and the Intrinsic subtype (IS) by Prosigna were applied to analyze genomic profile including mutations (mut) and copy number variants (CNV) of 161 genes. We evaluated clinical and molecular characteristics, TT and the impact of molecular alterations (alt) on treatment decision.
Results
Since November 2021, 64 pts were included, with evaluable genomic results in 54 (29 metastasis and 25 primary tumors). Median age was 59y (37-82). Twenty-three out of 53 (43.4%) pts with hormonal receptor (HR) positive HER2-negative ABC had been treated with >1 line (L) hormone therapy. Thirty-three pts (51.6%) had not received any prior chemotherapy L, 18 (28.1%) 1L, and 13 (20.3%) 2L. The IS distribution was 24 (44.4%) luminal B, 20 (37%) luminal A, 5 HER2-enriched, 5 basal-like (9.3% each), concordant with surrogate subtypes by IHQ in 70.6 %. More than 60 molecular alt were identified in 35 genes (median of 2 alt/patient); 1) mut: 21 (38.8 %) in PI3KCA (84.2% in HR+/HER2- tumors) and 17 (31.5%) in TP53 and 2) CNVs: 14 (25.9%) in FGFR1 and 13 in FGF19 (24%), 12 in CCND1 and ERBB2 (17.7% each). PI3KCA-mut was associated with a lower incidence of other alt compared to non-mut tumors (15 vs 52 additional alt, respectively: Chi-square, p=0.001). Six pts had died at the time of analysis with a median Overall Survival (OS) of 3.4 years. Triple Negative ABC, TP53 and PTEN mut were independently associated with worse progression free survival to 1L and OS (p<0.001). To date, 6 pts (11.1%) have received TT, mainly for PI3KCA mut and up to 25 (39.1%) will be considered for TT at progression.
Conclusions
Based on NGS data, more than 10% of pts benefitted from targeted therapy at the time of analysis, with expected benefit for additional 20%. Noteworthy, NGS adds prognostic information and better selection of sequential therapies. NGS is a key tool for personalised therapies in ABC, requiring more research to optimize its use.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Hospital Germans Trias i Pujol.
Disclosure
M.A. Bergamino: Non-Financial Interests, Personal, Invited Speaker: Eisai; Non-Financial Interests, Personal, Advisory Board: AstraZeneca; Non-Financial Interests, Personal, Funding: Novartis.M. Romeo Marin: Financial Interests, Personal, Funding: GSK, AstraZeneca, Clovis, MSD. M. Margeli Vila: Financial Interests, Personal, Funding: Novartis, Pfizer, Lilly, Gilead, Pierre Fabre, MSD. All other authors have declared no conflicts of interest.
Resources from the same session
157P - PCM4EU academy: An educational program for precision oncology
Presenter: Loic Verlingue
Session: Cocktail & Poster Display session
Resources:
Abstract
158P - Enhancing the communication of genomic results: Understanding patient and clinician perspectives
Presenter: Eleanor Johnston
Session: Cocktail & Poster Display session
Resources:
Abstract
159P - Precision medicine-based platform to guide the treatment of EML4-ALK fusion lung cancers and other NSCLC
Presenter: Nathan Merrill
Session: Cocktail & Poster Display session
Resources:
Abstract
160P - CICLADES-CE study: Genomic signatures detected in DNA from FFPE samples of patients with advanced or metastatic breast cancers treated with anti-aromatase and CDK4/6 inhibitors
Presenter: Margaux BETZ
Session: Cocktail & Poster Display session
Resources:
Abstract
161P - PDL1 expression and its relation to EML4-ALK gene variants in metastatic lung adenocarcinoma: A single-center real-world experience
Presenter: Santhosh Meedimale
Session: Cocktail & Poster Display session
Resources:
Abstract
164P - Clinical utility of comprehensive molecular profiling tests for advanced gastrointestinal tumors
Presenter: Alexandra Lebedeva
Session: Cocktail & Poster Display session
Resources:
Abstract
165P - Evaluation of the mutational profile in patients with metastatic non-small cell lung carcinoma diagnosed in a tertiary hospital which was performed by NGS method
Presenter: Kankan Deka
Session: Cocktail & Poster Display session
Resources:
Abstract
166P - Targeted next-generation sequencing as reliable detection of genetic profile for cancer treatment to guide oncologists in Pakistan
Presenter: Zeeshan Ahmed
Session: Cocktail & Poster Display session
Resources:
Abstract
167P - Molecular analysis of gastrointestinal stromal tumor (GIST): The experience of Regina Elena National Cancer Institute
Presenter: Andrea Torchia
Session: Cocktail & Poster Display session
Resources:
Abstract
168P - Usefulness of liquid biopsy in the management of patients with advanced or metastatic pancreatic cancer
Presenter: Jorge Iranzo Barreira
Session: Cocktail & Poster Display session
Resources:
Abstract